Author: Yasunori Watanabe; Joel D. Allen; Daniel Wrapp; Jason S. McLellan; Max Crispin
Title: Site-specific analysis of the SARS-CoV-2 glycan shield Document date: 2020_3_28
ID: 63j4qc7d_9
Snippet: There are three sites on SARS-CoV-2 that are predominantly oligomannose-type: N234, N709 and N801. The predominant structure observed at each site, with the exception of N234, is Man5GlcNAc2, which demonstrates that these sites are largely accessible to a ï¡1,2mannosidases but are poor substrates for GlcNAcT-I, which is the gateway enzyme in the formation of hybrid-and complex-type glycans in the Golgi apparatus. The stage at which processing is.....
Document: There are three sites on SARS-CoV-2 that are predominantly oligomannose-type: N234, N709 and N801. The predominant structure observed at each site, with the exception of N234, is Man5GlcNAc2, which demonstrates that these sites are largely accessible to a ï¡1,2mannosidases but are poor substrates for GlcNAcT-I, which is the gateway enzyme in the formation of hybrid-and complex-type glycans in the Golgi apparatus. The stage at which processing is impeded is a signature related to the density and presentation of glycans on the viral spike. For example, the more densely glycosylated spikes of HIV-1 Env and Lassa virus GPC give rise to numerous sites dominated by Man9GlcNAc2 [20] [21] [22] 26 .
Search related documents:
Co phrase search for related documents- Lassa virus and oligomannose type: 1, 2
- Lassa virus and viral spike: 1
- numerous site and site observe: 1
- oligomannose type and SARS site: 1, 2
- oligomannose type and viral spike: 1, 2, 3, 4
- oligomannose type and viral spike glycan: 1
- predominant structure and viral spike: 1
- SARS site and site observe: 1
- SARS site and viral spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
Co phrase search for related documents, hyperlinks ordered by date